Details

Autor(en) / Beteiligte

• Bai, Haotian
• Cui, Yutao
• Wang, Chenyu
• Wang, Zhonghan
• Luo, Wenbin
• Liu, Yuzhe
• Leng, Yi
• Wang, Jincheng
• Li, Zuhao
• Liu, He

Titel

3D printed porous biomimetic composition sustained release zoledronate to promote osteointegration of osteoporotic defects

Ist Teil von

• Materials & design, 2020-04, Vol.189, p.108513, Article 108513

Ort / Verlag

Elsevier Ltd

Erscheinungsjahr

2020

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Patients with osteoporosis are more likely to suffer prosthesis displacement, subsidence or periprosthesis fracture after prosthesis replacement. This is due to excessive osteoclast activity and a lack of bone marrow mesenchymal stem cell (BMSC) integration at the implant-bone interface locally in the setting of osteoporosis. In order to inhibit local excessive bone resorption and promote bone integration, we have constructed a porous titanium/poloxamer 407 hydrogel system loaded with zoledronate (ZOL), a bisphosphonate, to promote osteointegration in a rabbit model of osteoporosis. This composite scaffold (ZOL/gTi) showed good biocompatibility and sustained ZOL release along with the degradation of hydrogel. Not only does this system provide a three-dimensional structural network for BMSC proliferation but also locally released ZOL promotes proliferation and osteogenic differentiation while inhibiting osteoclast differentiation of BMSCs in vitro. After implantation of ZOL/gTi into a distal femoral defect in the rabbits, micro-CT, histological, push-out, as well as genetic and protein analyses revealed significant promotion of osteointegration with the aid of this composite scaffold. Here, we provide an important theoretical basis for the research and development of bioactive implant interfaces for patients with osteogenic defects, such as osteoporosis. [Display omitted] •A scaffold is fabricated as a zoledronate release system composed of 3D-printed Ti6Al4V and temperature-sensitive hydrogel.•The composite scaffold induced osteogenic differentiation and inhibited osteoclast gene expression via zoledronate release.•Improved osseointegration and stability between the scaffold and bone tissue in osteoporotic bone defects are achieved.